Microbials for the production of monoclonal antibodies and antibody fragments

Autor:	Oliver, Spadiut, Simona, Capone, Florian, Krainer, Anton, Glieder, Christoph, Herwig
Rok vydání:	2013
Předmět:	recombinant protein production Antibodies Monoclonal Bioengineering macromolecular substances Saccharomyces cerevisiae Review antibody fragment Pichia Recombinant Proteins Cell Line mammalian cell monoclonal antibody Escherichia coli Animals Humans microbial organism Immunoglobulin Fragments
Zdroj:	Trends in Biotechnology
ISSN:	1879-3096
Popis:	Highlights • Glycosylated full length antibodies are currently produced in mammalian cells. • Antibody fragments can be produced in microbial organisms. • Strain engineering allows production of full length antibodies in microbials. • Microbials provide several advantages over mammalian cells. Monoclonal antibodies (mAbs) and antibody fragments represent the most important biopharmaceutical products today. Because full length antibodies are glycosylated, mammalian cells, which allow human-like N-glycosylation, are currently used for their production. However, mammalian cells have several drawbacks when it comes to bioprocessing and scale-up, resulting in long processing times and elevated costs. By contrast, antibody fragments, that are not glycosylated but still exhibit antigen binding properties, can be produced in microbial organisms, which are easy to manipulate and cultivate. In this review, we summarize recent advances in the expression systems, strain engineering, and production processes for the three main microbials used in antibody and antibody fragment production, namely Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::c0129bd1e4d14307efe216097a769e2d https://pubmed.ncbi.nlm.nih.gov/24183828 Zobrazit plný text záznamu Full Text from ScienceDirect